Travere Therapeutics Rallies To Buy Point As Kidney Drug Sales Rocket 182%; Anticipates FDA Priority Review For FSGS Treatment
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
